55894-16-1

Usage

Uses

Used in Pharmaceutical Industry:
Phosphonium, (2-methoxyethyl)triphenyl-, bromide is used as an intermediate in the synthesis of (Z)-Triprolidine Oxalate Salt (T814007) for its role in producing an antihistaminic agent with anticholinergic properties. Triprolidine is employed to treat and prevent symptoms associated with allergies, such as itching, swelling, and rhinitis. Its antihistaminic and anticholinergic effects make it a valuable component in the development of medications for allergy relief.
Additionally, Triprolidine is used in combination with cold medicine to provide relief for flu-like symptoms, such as nasal congestion, sneezing, and coughing. The combination of Triprolidine with other active ingredients in cold medicines helps to alleviate the discomfort and inconvenience caused by the common cold, making it a versatile compound in the pharmaceutical sector.

InChI:InChI=1/C21H22OP/c1-22-17-18-23(19-11-5-2-6-12-19,20-13-7-3-8-14-20)21-15-9-4-10-16-21/h2-16H,17-18H2,1H3/q+1

Upstream product

• 603-35-0 triphenylphosphine 
• 6482-24-2 2-Bromoethyl methyl ether 
• 67-56-1 methanol 
• 540-51-2 2-bromoethanol 
• 7237-34-5 2-(hydroxyethyl)triphenylphosphonium bromide 

Downstream Products

• 21331-80-6 [2-(dimethylamino)ethyl]triphenylphosphonium bromide 
• 21277-56-5 [2-(N-piperidino)ethyl]triphenylphosphonium bromide 
• 21331-68-0 [2-(N-morpholino)ethyl]triphenylphosphonium bromide 
• 1226985-13-2 (1E,3Z)-(5-methoxypenta-1,3-dienyl)benzene 
• 112655-08-0 ((1E,3E)-5-methoxypenta-1,3-dien-1-yl)benzene 
• 1122568-72-2 tert-butyl [3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}-2-(4-{3-[3-methoxyprop-1-en-1-yl]pyridin-2-yl}-2-methylphenyl)propyl]carbamate 
• 887-21-8 2-(diphenylphosphinyl)ethanol 
• 4336-76-9 (β-methoxyethyl)diphenylphosphine oxide 
• 23896-93-7 (α-methylbenzyl)diphenylphosphine oxide 
• 791-28-6 Triphenylphosphine oxide 
• 2096-78-8 vinyldiphenylphosphine oxide 
• 1476-07-9 cinnamyl ethyl ether 
• 16277-67-1 (Z)-(3-methoxyprop-1-en-1-yl)benzene 

Relevant academic research and scientific papers

2,6-diisopropylphenol compound as well as preparation method and application thereof

The invention relates to a 2,6-diisopropylphenol compound as well as a preparation method and application thereof. The invention particularly relates to a compound shown as a general formula (A) in the description, a preparation method and application of the compound in preparation of anesthetic drugs and drugs for treating cerebral arterial thrombosis. The compound shown in the formula A is characterized in that an olefinic bond in the formula is of a trans-structure; and R1 is selected from CH2OR2 and COOR3.

Synthesis of 2-(N-disubstituted amino)ethyltriphenylphosphonium bromides

2-(N-Disubstituted amino)ethyltriphenylphosphonium bromides are prepared in quantitative yields with high purity by reacting secondary amines with 2-methoxyethyltriphenylphosphonium bromide under aqueous conditions. The differential reactivity of this reagent offers advantages for the preparation of aminoethyltriphenylphosphonium bromides possessing nucleophiles such as hydroxy groups.

A PROCESS FOR THE SYNTHESIS OF (E) -2-[1 - (4 - METHYL PHENYL) -3-(1-PYRRONYL)-1 - PROPENYL] PYRIDINE (TRIPROLIDINE)

A Process for the synthesis of (E) - 2 - [1 - (4 - methyl phenyl) -3- (1- pyrrolidinyl)-l- propenyl] pyridine (TRIPROLIDINE) by reacting 2-(l-pyrrolidino)ethyl triphenyl phosphonium bromide with 2-(p-toluoyl) pyridine in presence of aprotic solvent and a base, isomeising in presence of acid catalyst.

4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS

Compounds of the present invention having the formula (I) exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

Pyrrolidinic and piperidinic ring fission by conjugate elimination

Treating N-substituted pyrrolidines and piperidines bearing an allylic chain α to the nitrogen with strong bases leads to the opening of the heterocycle and provides 1,3-dienes disubstituted with an alkoxy and an aminoalkyl chain. The effects of the base and the solvent have been studied, as well as the influence of the ring size and the nitrogen substituent. The results obtained suggest a possible pre-chelation of the base cation before the deprotonation.

ALKALINE HYDROLYSIS OF β AND γ-FUNCTIONAL PHOSPHONIUM SALTS

A model study of alkaline hydrolysis of β- and γ-heterosubstituted phosphonium salts has been made and used as a synthetic method to obtain diphosphine dioxides affording additional coordination sites in an alkyl chain linked to phosphorus.After synthesis of the corresponding salts, anomalous fragmentations, such as inversion in cleavage selectivity or participation of the reaction solvent, have been pointed out in alkaline hydrolysis of β-functional phosphonium salts.A mechanism is suggested to account for the presence of all compounds detected.In the case of γ-functional phosphonium salts, the alkaline hydrolysis leads only to predicted compounds corresponding to the usual selective cleavage of one phenyl group.The results observed have been used to synthesize symmetric and asymmetric diphosphine dioxides with ether substituted side chains. - Key words: Phosphonium salt, phosphine oxide, diphosphine dioxides, alkaline hydrolysis, cleavage, mechanism.

Synthesis and antitumor properties of some isoindolylalkylphosphonium salts

Antitumor evaluation of 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl) ethyltriphenylphosphonium bromide (1) revealed significant activity in P-388 lymphocytic leukemia (T/C = 160%). As a follow-up to this chemical lead, a series of closely related phosphonium salts was prepared in which the 1,3-dihydro-1,3-dioxo-2H-isoindole ring system was maintained or in which it was replaced by other moieties such as maleimido, bromo, methoxy, and isoindoline. Syntheses generally involved treatment of the appropriate N-(bromoalkyl)phthalimide with the required phosphine or condensation of the K salt of the substituted imide with β-(bromoethyl) triphenylphosphonium bromide. From the biological data obtained for these compounds, several requirements can be defined for substantial antileukemic activity. Of utmost importance is the presence of a triarylphosphonium halide moiety, coupled to an alkyl chain of two or three carbon atoms. The preferred terminus of the alkyl chain is the 1,3-dihydro-1,3-dioxo-2H-isoindole ring system, although the observed activity of β-(bromoethyl)triphenylphosphonium bromide (T/C = 127%) would suggest that a superior carrier molecule could be developed.